• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      FDA panel backs NovoCure's cancer treatment device

      Posted Atglobes.co.il

      NovoCure Ltd announced that the US Food and Drug Administration (FDA) Neurological Devices Advisory Panel voted that its device for treating supra-tentorial glioblastoma multiforme (GBM) tumors is safe This is not formal approval for the device, which is used after surgery and radiation treatment, but the FDA tends to follow the recommendations of its panels.

      The committee's recommendation followed a review of data from the EF-11 Trial, a randomized phase III trial for 237 patients with glioblastoma tumors that had recurred or progressed despite previous treatments. The committee received and considered the final data from the EF-11 Trial, which updated data previously reported at the American Society for Clinical Oncology Annual Meeting in June 2010. The trial demonstrated that patients treated with the NovoTTF alone achieved a comparable overall survival time to patients treated with the physician's choice of the best chemotherapy. Patients treated with the NovoTTF also had higher rates of progression free survival at six months and higher tumor response rates compared with chemotherapy treated patients in the trial.

      NovoTTF treated patients reported better quality of life scores and fewer side effects during the trial compared to patients treated with chemotherapy. The NovoTTF's most commonly reported side effect was a mild-to-moderate rash beneath the electrodes.

      NovoCure CEO Asaf Danziger said, "We look forward to working with the FDA to bring this novel, important therapy to patients as soon as possible,"

      The FDA is currently reviewing a pre-market approval (PMA) application for the NovoTTF for this indication.

      NovoCure was founded in 2000 by Asaf Danziger and Prof. Yoram Palti and has raised $15 million to date from Pfizer, Johnson & Johnson and Index Ventures.

      Mar 25, 2011


       

      Share this Article!

    Back to top^